Effectiveness and Safety of CELSTAT for Hemostasis in Intraoperative Tissue Bleeding

NCT02640235 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2020-08-03

Study results available
· View outcomes & findings →

Summary

The study is to evaluate the effectiveness and safety of CELSTAT vs active control.

Conditions

  • Bleeding Active

Interventions

DEVICE

CELSTAT

DEVICE

Surgicel Original

Sponsors & Collaborators

  • Baxter Healthcare Corporation

    lead INDUSTRY

Principal Investigators

  • Qing Li, MD · Baxter Healthcare Corporation

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-24
Primary Completion
2017-07-21
Completion
2017-10-18

Countries

  • United States
  • Czechia
  • Germany
  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02640235 on ClinicalTrials.gov